Soria Irene, Alvarez Javier, Manzano Ana I, López-Relaño Juan, Cases Bárbara, Mas-Fontao Ana, Cañada F Javier, Fernández-Caldas Enrique, Casanovas Miguel, Jiménez-Barbero Jesús, Palomares Oscar, Viñals-Flórez Luis M, Subiza José L
Inmunotek S.L., Alcalá de Henares, Spain.
Alergovet S.L., Madrid, Spain.
Vet Immunol Immunopathol. 2017 Aug;190:65-72. doi: 10.1016/j.vetimm.2017.07.004. Epub 2017 Jul 23.
We have recently reported that grass pollen allergoids conjugated with nonoxidized mannan of Saccharomyces cerevisae using glutaraldehyde results in a novel hypoallergenic mannan-allergen complex with improved properties for allergen vaccination. Using this approach, human dendritic cells show a better allergen uptake and cytokine profile production (higher IL-10/IL-4 ratio) for therapeutic purposes. Here we aim to address whether a similar approach can be extended to dogs using canine dendritic cells. Six healthy Spanish Greyhound dogs were used as blood donors to obtain canine dendritic cells (DC) derived from peripheral blood monocytes. Allergens from Dermatophagoides farinae mite were polymerized and conjugated with nonoxidized mannan. Nuclear magnetic resonance (NMR), gel electrophoresis (SDS-PAGE), immunoblotting and IgE-ELISA inhibition studies were conducted to evaluate the main characteristics of the allergoid obtained. Mannan-allergen conjugate and controls were assayed in vitro for canine DC uptake and production of IL-4 and IL-10. The results indicate that the conjugation of D. farinae allergens with nonoxidized mannan was feasible using glutaraldehyde. The resulting product was a polymerized structure showing a high molecular weight as detected by NMR and SDS-PAGE analysis. The mannan-allergen conjugate was hypoallergenic with a reduced reactivity with specific dog IgE. An increase in both allergen uptake and IL-10/IL-4 ratio was obtained when canine DCs were incubated with the mannan-allergen conjugate, as compared with the control allergen preparations (unmodified D. farinae allergens and oxidized mannan-allergen conjugate). We conclude that hypoallergenic D. farinae allergens coupled to nonoxidized mannan is a novel allergen preparation suitable for canine allergy immunotherapy targeting dendritic cells.
我们最近报道,使用戊二醛将草花粉变应原与酿酒酵母的非氧化甘露聚糖偶联,可形成一种新型的低变应原性甘露聚糖 - 变应原复合物,其具有改善的变应原疫苗接种特性。采用这种方法,人树突状细胞在治疗目的上表现出更好的变应原摄取和细胞因子谱产生(更高的IL - 10/IL - 4比值)。在此,我们旨在探讨类似的方法是否可以扩展到犬类,使用犬树突状细胞。六只健康的西班牙灵缇犬作为献血者,以获取源自外周血单核细胞的犬树突状细胞(DC)。来自粉尘螨的变应原进行聚合,并与非氧化甘露聚糖偶联。进行了核磁共振(NMR)、凝胶电泳(SDS - PAGE)、免疫印迹和IgE - ELISA抑制研究,以评估所得变应原的主要特性。在体外检测甘露聚糖 - 变应原偶联物和对照物对犬DC摄取以及IL - 4和IL - 10产生的影响。结果表明,使用戊二醛将粉尘螨变应原与非氧化甘露聚糖偶联是可行的。通过NMR和SDS - PAGE分析检测,所得产物为高分子量的聚合结构。甘露聚糖 - 变应原偶联物具有低变应原性,与特异性犬IgE的反应性降低。与对照变应原制剂(未修饰的粉尘螨变应原和氧化甘露聚糖 - 变应原偶联物)相比,当犬DC与甘露聚糖 - 变应原偶联物孵育时,变应原摄取和IL - 10/IL - 4比值均增加。我们得出结论,与非氧化甘露聚糖偶联的低变应原性粉尘螨变应原是一种新型变应原制剂,适用于针对树突状细胞的犬类变应性免疫疗法。